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Background
The European AIDS Clinical Society (EACS) Guidelines cover key aspects of HIV management with
major updates every two years.
Guideline highlights
The 2019 Guidelines were extended with a new section focusing on drug–drug interactions and
other prescribing issues in people living with HIV (PLWH). The recommendations for treatment-
na€ıve PLWH were updated with four preferred regimens favouring unboosted integrase inhibitors.
A two-drug regimen with dolutegravir and lamivudine, and a three-drug regimen including
doravirine were also added to the recommended initial regimens. Lower thresholds for
hypertension were expanded to all PLWH and for cardiovascular disease prevention, the 10-year
predicted risk threshold for consideration of antiretroviral therapy (ART) modification was lowered
from 20% to 10%. Frailty and obesity were added as new topics. It was specified to use urine
albumin to creatinine ratio to screen for glomerular disease and urine protein to creatinine ratio
for tubular diseases, and thresholds were streamlined with the Kidney Disease: Improving Global
Outcomes (KDIGO) recommendations. Hepatitis C virus (HCV) treatment recommendations were
split into preferred and alternative treatment options. The algorithm for management of recently
acquired HCV infection was updated and includes recommendations for early chronic infection
management. Treatment of resistant tuberculosis (TB) was streamlined with the World Health
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Organization (WHO) recommendations, and new tables on immune reconstitution inflammatory
syndrome, on when to start ART in the presence of opportunistic infections and on TB drug dosing
were included.
Conclusions
The EACS Guidelines underwent major revisions of all sections in 2019. They are available in four
different formats including a new interactive web-based version and are translated into Chinese,
French, German, Japanese, Portuguese, Russian and Spanish.
Keywords: antiretroviral treatment, comorbidities, drug–drug interactions, European AIDS Clinical
Society (EACS) Guidelines, hepatitis B virus, hepatitis C virus, HIV, opportunistic infections,
prescribing in elderly patients
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The European AIDS Clinical Society (EACS)
Guidelines
As several countries are lacking or infrequently update
national HIV guidelines, the EACS Guidelines have since
2005 provided recommendations that are independent of
geographical region and levels of care. Acknowledging
that HIV care extends far beyond antiretroviral treatment
(ART), the EACS Guidelines also provide guidance on
several other key aspects related to HIV management.
In 2019, the EACS Guidelines underwent major revi-
sions of all sections [1]. One of the most essential changes
includes a new panel focusing on drug–drug interactions
(DDIs) and other prescribing issues in people living with
HIV (PLWH) in acknowledgement of the increased ageing
of PLWH and increasing risks of polypharmacy.
Bictegravir (BIC) and doravirine (DOR) were released since
the last major revision and have been included in all sections.
In addition, older drugs that are now rarely used, including
several older boosted protease inhibitors (PI/bs), didanosine
and stavudine, were removed from most sections.
To ensure easy access to the Guidelines, a new format
in the form of an interactive web-based version was
introduced (https://eacs.sanfordguide.com) in 2019. The
Guidelines remain available in print as a booklet, online
as a pdf (https://www.eacsociety.org/files/2019_guideline
s-10.0_final.pdf) and as a free App for IOS and Android
devices produced with the Sanford Group. The EACS
Guidelines are translated into Chinese, French, German,
Japanese, Portuguese, Russian and Spanish.
The Guideline review process
The Guidelines undergo major revisions every second
year, and minor revisions in the years in between, as pre-
viously described [2]. Interim updates may be performed
in the case of new key data emerging between scheduled
updates. Meetings are held at regular intervals but can
also be set up at short notice when necessary.
Each of the Guideline sections is created by a panel of
experts governed by a three-person leadership group. The
Guidelines are managed by a Guidelines Chair and Coor-
dinator; details have previously been described [2]. As
also previously reported, the recommendations provided
in the EACS Guidelines are based on evidence whenever
possible, and, in the rare instances where adequate evi-
dence is unavailable, based on expert opinions [2].
The Guidelines are extensively cross-reviewed by the
panellists, and by representatives from the community
and from Women Against Viruses in Europe (WAVE).
Conflict of interest statements are required for all mem-
bers and can be provided upon request.
In the following, the most important changes made in
version 10.0 for each section of the Guidelines are
described.
ART section
In the 2019 version, the layout for initial ART regimens,
treatment in pregnancy/women wishing to conceive and
in persons coinfected with tuberculosis (TB) were made
uniform to ensure consistency.
Before initiating ART, it is recommended to consider if a
woman is pregnant or wishes to conceive, and if the person
has an opportunistic infection or any potential treatment-
limiting comorbidities. In addition, it is recommended to
consider if the person is at risk of DDIs or if the person has
swallowing difficulties. In all these instances, the Guideli-
nes provide management recommendations.
Among the recommended first-line regimens for ART-
na€ıve PLWH, EACS recommends four preferred options
consisting of two nucleoside reverse transcriptase inhibi-
tors [NRTIs; abacavir (ABC)/lamivudine (3TC), tenofovir
alafenamide (TAF)/emtricitabine (FTC), tenofovir diso-
proxil fumarate (TDF)/TFC or TDF/3TC] in combination
with an unboosted integrase strand transfer inhibitor
[INSTI; dolutegravir (DTG), BIC or raltegravir (RAL)]
(Table 1). Among these preferred regiments, EACS favour
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those with a high genetic barrier (DTG or BIC) as a third
agent.
Other recommended first-line regimens include one
two-drug combination with an NRTI (3TC) plus an INSTI
(DTG), and three three-drug combinations with two NRTIs
(TAF/FTC, TDF/FTC or TDF/3TC) plus a nonnucleoside
reverse transcriptase inhibitor [NNRTI; DOR or rilpivirine
(RPV)] or plus a boosted protease inhibitor [PI/b;
cobicistat (COBI)- or ritonavir (RTV)-boosted darunavir
(DRV/c or DRV/r)] (Table 1).
The alternative regimen recommendations to be used
when none of the preferred regimens are available are
shown in Table 1.
The following two-drug combinations are recom-
mended as possible switch strategies; 3TC with DTG,
DRV/b or boosted atazanavir (ATV/b) or DTG plus RPV.
Table 1 Combination antiretroviral therapy (ART) regimens for treatment-na€ıve adult people living with HIV (PLWH)
Regimen Main requirements Additional guidance (footnotes)
Recommended regimens
2 NRTIs + INSTI (preferred)
ABC/3TC + DTG
ABC/3TC/DTG
HLA-B*57:01 negative
HBsAg negative
I (ABC: HLA-B*57:01, cardiovascular risk)
TAF/FTC or TDF/FTC or TDF/3TC
+ DTG
II (TDF: prodrug types. Renal and bone toxicity. TAF dosing)
III (Weight increase)
TAF/FTC/BIC
TAF/FTC or TDF/FTC or TDF/3TC
+ RAL qd or bid
II (TDF: prodrug types. Renal and bone toxicity. TAF dosing)
IV (RAL: dosing)
1 NRTI + INSTI
DTG + 3TC HBsAg negative
HIV VL < 500 000 copies/mL
CD4 count > 200 cells/µL
2 NRTIs + NNRTI
TAF/FTC or TDF/FTC or TDF/3TC
+ DOR
TDF/3TC/DOR
II (TDF: prodrug types. Renal and bone toxicity. TAF dosing)
V (DOR: HIV-2)
TAF/FTC or TDF/FTC or TDF/3TC
+ RPV
TAF/FTC/RPV
TDF/FTC/RPV
CD4 count > 200 cells/µL,
HIV VL < 100 000 copies/mL
Not on proton pump inhibitor
With food
II (TDF: prodrug types. Renal and bone toxicity. TAF dosing)
VI (RPV: HIV-2)
2 NRTIs + PI/r or PI/c
TAF/FTC or TDF/FTC or TDF/3TC
+ DRV/c or DRV/r
TAF/FTC/DRV/c
With food II (TDF: prodrug types. Renal and bone toxicity. TAF dosing)
VII (DRV/r: cardiovascular risk)
Alternative regimens
2 NRTIs + INSTI
ABC/3TC + RAL qd or bid HBsAg negative
HLA-B*57:01 negative
I (ABC: HLA-B*57:01, cardiovascular risk)
IV (RAL: dosing)
TDF/FTC/EVG/c
TAF/FTC/EVG/c
With food II (TDF: prodrug types. Renal and bone toxicity)
VIII (EVG/c: use in renal impairment)
2 NRTIs + NNRTI
ABC/3TC + EFV HLA-B*57:01 negative
HBsAg negative
HIV VL < 100 000 copies/mL
At bedtime or 2 h before dinner
I (ABC: HLA-B*57:01, cardiovascular risk)
IX (EFV: suicidality. HIV-2 or HIV-1 group 0)
TAF/FTC or TDF/FTC or TDF/3TC
+ EFV
TDF/FTC/EFV
At bedtime or 2 h before dinner II TDF: prodrug types. Renal and bone toxicity. TAF dosing)
IX (EFV: suicidality. HIV-2 or HIV-1 group 0)
2 NRTIs + PI/r or PI/c
ABC/3TC + ATV/c or ATV/r HLA-B*57:01 negative
HBsAg negative
HIV VL < 100 000 copies/mL
Not on proton pump inhibitor
With food
I (ABC: HLA-B*57:01, cardiovascular risk)
X (ATV/b and renal toxicity)
ABC/3TC + DRV/c or DRV/r HLA-B*57:01 negative
HBsAg negative
With food
I (ABC: HLA-B*57:01, cardiovascular risk)
VII (DRV/r and cardiovascular risk)
TAF/FTC or TDF/FTC or TDF/3TC
+ ATV/c or ATV/r
Not on proton pump inhibitor
With food
II (TDF: prodrug types. Renal and bone toxicity. TAF dosing)
X (ATV/b: renal toxicity)
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Three new tables were included for pregnant women
living with HIV or women wishing to conceive to specify
which drugs are considered safe and which to avoid.
EACS currently recommends not using DTG in women
who wish to conceive because of the reported higher risk
of neural tube defect if used preconception [3]. As a con-
sequence of insufficient data on safety and efficacy in
pregnancy, TAF, RAL once a day (qd), BIC and DOR are
currently not recommended in women who become preg-
nant while on ART. In addition, COBI boosting has
proved less robust than RTV boosting during pregnancy,
and therefore COBI-boosted elvitegravir (EVG/c) is not
recommended and ATV or DRV should be boosted only
with RTV in women who become pregnant while on ART.
The preferred initial options for ART-na€ıve pregnant
women include combinations of two NRTIs (ABC/3TC,
TDF/FTC or TDF/3TC) plus an INSTI [DTG, which can be
used after pregnancy week 8, or RAL twice a day (bid)].
The recommended regimens include two NRTIs (TDF/FTC
or TDF/3TC) plus a PI/r (DRV/r). Alternative regimens to
be considered consist of two NRTIs (ABC/3TC, TDF/FTC
or TDF/3TC) plus an NNRTI [efavirenz (EFV) or RPV] or
plus a PI/r (ATV/r or DRV/r). A section on labour and
breastfeeding was further added.
For PLWH coinfected with susceptible TB, the recom-
mended ART regimens to be used with rifampicin include
the combination of two NRTIs (TDF/FTC, TDF/3TC or
ABC/3TC) plus an NNRTI (EFV), or for alternative regi-
mens plus an INSTI (DTG bid or RAL bid). An updated
table further describes the most relevant DDIs when ART
is co-administered with rifampicin or rifabutin.
For post-exposure prophylaxis (PEP), additional regi-
men combinations with TAF/FTC, RAL qd and BIC were
included. For pre-exposure prophylaxis (PrEP), use of
daily TAF/FTC was included as a possible alternative in
men who have sex with men and transgender women.
Section on DDIs and other prescribing
issues
All DDI tables have been organized in a separate section
devoted to issues related to prescribing ART and other
co-medication in PLWH. The DDI tables each provide an
overview of the interaction potential between individual
antiretroviral drugs and the most commonly used co-
medications within a therapeutic area.
Two new tables have been added on dose adjustment
in renal impairment for commonly co-administered drugs
Table 1 (Continued)
Regimen Main requirements Additional guidance (footnotes)
Other combinations
RAL 400 mg bid + DRV/c or DRV/r HBsAg negative
HIV VL < 100 000 copies/mL
CD4 > 200 cells/µL
With food
VII (DRV/r: cardiovascular risk)
Additional guidance: (I) ABC contraindicated if HLA-B*57:01 positive. Even if HLA-B*57:01 negative, counselling on hypersensitivity reaction risk still
mandatory. ABC should be used with caution in persons with a high CVD risk (> 10%). (II) In certain countries, TDF is labelled as 245 mg rather than
300 mg to reflect the amount of the prodrug (tenofovir disoproxil) rather than the fumarate salt (tenofovir disoproxil fumarate). There are available
generic forms of TDF, which instead of fumarate use phosphate, maleate, and succinate salts. They can be used interchangeably. When available, com-
binations containing TDF can be replaced by the same combinations containing TAF. TAF is used at 10 mg when coadministered with drugs that inhibit
p-glycoprotein (P-gp), and at 25 mg when co-administered with drugs that do not inhibit P-gp. The decision whether to use TDF or TAF depends on
individual characteristics as well as availability. So far, there are only limited long-term data on TAF. If the antiretroviral (ART) regimen does not
include a booster, TAF and TDF have similar short-term risks of renal adverse events leading to discontinuation and bone fractures.
TAF*** should be considered as a first choice**** over TDF in individuals with:
(1) established or high risk of chronic kidney disease (see Guideliness page 64); (2) co-administration of medicines with nephrotoxic drugs or prior TDF
toxicity (see Guidelines page 65); (3) osteoporosis/progressive osteopenia, high fracture risk asessement tool score or risk factors (see Guidelines page
61); (4) history of fragility fracture (see Guidelines pages 61 and 63).
***There are limited data on use of TAF with estimated glomerular filtration rate (eGFR) < 30 mL/min;
****Expert opinion pending clinical data.
(III) Two randomized controlled trials (performed in South Africa and Cameroon) showed that, in comparison with EFV, treatment with DTG in na€ıve
persons was associated with increased weight gain when combined with TAF/FTC, TDF/FTC or TDF/3TC. The effect on increased weight was more impor-
tant for women under treatment containing both DTG and TAF (reference [12], [13] in the Guidelines). (IV) RAL can be given as RAL 400 mg bid or
RAL 1200 mg (two 600 mg tablets) qd. Note: RAL qd should not be given in the presence of an inducer (i.e. TB drugs or antiepileptics) or divalent
cations (i.e. calcium, magnesium or iron), in which case RAL should be used bid. (V) DOR is not active against HIV-2. (VI) RPV is not active against
HIV-2. (VII) A single study has shown an increase in CVD risk with cumulative use of DRV/r (reference [14] in the Guidelines). (VIII) TDF/FTC/EVG/c to
be used only if eGFR ≥ 70 mL/min. It is recommended that TDF/FTC/EVG/c is not initiated in persons with eGFR < 90 mL/min unless this is the pre-
ferred treatment. (IX) EFV: not to be given if history of suicide attempts or mental illness; not active against HIV-2 and HIV-1 group O strains. (X)
Potential renal toxicity with ATV/b.
NRTI, nucleoside reverse transcriptase inhibitor; INSTI, integrase strand transfer inhibitor; HLA, human leucocyte antigen; ABC, abacavir; HBsAg, hepati-
tis B virus surface antigen; 3TC, lamivudine; DTG, dolutegravir; TAF, tenofovir alafenamide; FTC, emtricitabine; TDF, tenofovir disoproxil fumarate), BIC,
bictegravir; DOR, doravirine; RAL, raltegravir; qd, once daily; bid, twice a day; VL, viral load; RPV, rilpivirine; PI/r, ritonavir-boosted protease inhibitor;
PI/c, cobicistat-boosted protease inhibitor; EVG, elvitegravir; NNRTI, nonnucleoside reverse transcriptase inhibitor; ATV, atazanavir; CVD, cardiovascular
disease.
© 2020 The Authors.
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in PLWH and a list of the top ten drugs to avoid in
elderly PLWH to increase awareness of inappropriate drug
administration and dosing.
In addition, a new table was developed on the recom-
mended drug dosages for hormone therapy when used at
high doses for gender transitioning.
Detailed information on DDIs can be found in the Univer-
sity of Liverpool website www.hiv-druginteractions.org.
Comorbidity section
The comorbidity section continues to be the largest sec-
tion of the EACS Guidelines and provides screening and
management recommendations for the most common
comorbid conditions among PLWH and for conditions
that require specific guidance.
Given the increased prevalence of frailty in PLWH, a
new table outlines definitions, recommended assessments
and management to help identify those at frailty risk. For
some comorbidities [e.g. hypertension, nonalcoholic fatty
liver disease (NAFLD) and bone disease], different age-
specific guidance for diagnosis [e.g. using dual-energy X-
ray absorptiometry (DEXA) scan and liver fibrosis scores]
and management (e.g. for hypertension) is provided.
Recommendations to lower blood pressure targets to
systolic pressure < 130 mmHg and diastolic pressure
< 80 mmHg were previously introduced (v9.0) for high-
risk individuals; in 2019 (v10.0), these recommendations
were further broadened to apply to all PLWH. Further-
more, antihypertensive drug sequencing was amended.
The threshold for ART modification in relation to 10-
year predicted cardiovascular disease (CVD) risk has been
lowered from 20% to 10%. Similarly, lipid targets have
been lowered for both primary and secondary prophy-
laxis.
As obesity and weight increase have become more fre-
quent in PLWH, and this is a rapidly evolving field, an
addition on diagnosis, risk factors and management of
obesity was made to the existing chapter on lipoatrophy.
New data on weight increase related to use of INSTIs and
TAF were added to the table on potential adverse drug
effects.
In the liver section, a fourth step was added to the work-
up of persons with increased transaminases to include risk
stratification using aspartate aminotrabsferase to platelet
ratio (APRI), fibrosis-4 (FIB4), NAFLD fibrosis score and
transient elastography. Similarly, the screening recommen-
dation for hepatocellular carcinoma in noncirrhotic per-
sons with chronic HBV coinfection was amended in
collaboration with the viral hepatitis panel to include an
age threshold acknowledging the higher risk in those older
than 45 years [4]. The algorithm for surveillance for
Table 2 Preferred DAA HCV treatment options (except for persons pretreated with protease or NS5A inhibitors)
HCV GT Treatment regimen
Treatment duration and RBV usage
Noncirrhotic Compensated cirrhotic Decompensated cirrhotic CTP class B/C
1 and 4 EBR/GZR 12 weeksa Not recommended
GLE/PIB 8 weeks 12 weeks Not recommended
SOF/VEL 12 weeks 12 weeks with RBV
SOF/LDV  RBV 8–12 weeks without RBVb 12 weeks with RBVc
2 GLE/PIB 8 weeks 12 weeks Not recommended
SOF/VEL 12 weeks 12 weeks with RBV
3 GLE/PIB 8 weeksd 12 weeksd Not recommended
SOF/VEL  RBV 12 weekse 12 weeks with RBVf or 24 weeks without RBV
SOF/VEL/VOX - 12 weeks Not recommended
5 and 6 GLE/PIB 8 weeks 12 weeks Not recommended
SOF/LDV  RBV 12 weeks  RBVg 12 weeks with RBVc
SOF/VEL 12 weeks 12 weeks with RBV
CTP, child-Turcotte-Pugh; DAA, direct-acting antiviral; DCV, daclatasvir; DSV, dasabuvir; EBR, elbasvir; GLE, glecaprevir; GT, genotype; GZR, grazoprevir;
LDV, ledipasvir; NS5A, Nonstructural protein 5A; OBV, ombitasvir; PIB, pibrentasvir; PTV/r, paritaprevir/RTV; RAS, resistance-associated substitution;
RBV, ribavirin; SOF, sofosbuvir; VEL, velpatasvir; VOX, voxilaprevir.
a
Extension of treatment to 16 weeks and addition of RBV in PLWH with GT1a with baseline HCV RNA > 800 000 IU/mL and/or NS5A RASs causing at
least 5-fold reduction in activity of EBR to minimize the risk of treatment failure and in HCV GT4-experienced PLWH with HCV RNA > 800 000 IU/mL
at 8 weeks can be considered in GT1b treatment-na€ıve patients with F0–F2.
b
8 weeks of treatment without RBV only in treatment-na€ıve PLWH with F < 3 and baseline HCV RNA < 6 million IU/mL.
c
In persons intolerant to RBV, treatment may be prolonged to 24 weeks. RBV can be omitted in treatment-na€ıve or -experienced PLWH with compen-
sated cirrhosis without baseline NS5A RAS.
d
Treatment duration in HCV GT3 who failed previous treatment with interferon (IFN) and RBV  SOF or SOF and RBV should be 16 weeks.
e
Addition of RBV in treatment-experienced PLWH with baseline NS5A RASs, if RAS testing available; if these persons are intolerant to RBV, treatment
may be prolonged to 24 weeks without RBV.
f
If RAS testing is available and demonstrates absence of NS5A RAS Y93H, RBV can be omitted in treatment-na€ıve PLWH with compensated cirrhosis.
g
In treatment-experienced (exposure to IFN/RBV/SOF) PLWH, treat with RBV for 12 weeks or prolong treatment to 24 weeks without RBV.
© 2020 The Authors.
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varices and primary prophylaxis was updated to incorpo-
rate transient elastography (where available) with platelet
counts to determine indications for upper gastrointestinal
endoscopy. Finally, the diagnostics flow-chart for NAFLD
was revised to include the use of fibrosis scores.
Finally, in the renal subsection, it was specified to use
urine albumin to creatinine ratio to screen for glomerular
disease (such as diabetes and HIV-related disease), and
urine protein to creatinine ratio to screen for tubular dis-
eases (i.e. ART drug toxicity). The cut-off values for albu-
minuria and proteinuria have further been streamlined
with the Kidney Disease: Improving Global Outcomes
(KDIGO) recommendations [5].
Viral hepatitis coinfection section
This section was renamed Clinical management and treat-
ment of viral hepatitis co-infections in PLWH. The overall
structure of the section was also revised to improve read-
ability.
The first subsection contains general recommendations
on viral hepatitis coinfections in PLWH and focuses on
screening recommendations, measures of prevention and
complications related to viral hepatitis. A new table on
noninvasive liver fibrosis markers was introduced.
Another subsection focuses on treatment and monitor-
ing of PLWH coinfected with HBV and includes a part on
HBV reactivation related to immunosuppressive treatment
with monitoring and treatment recommendations strati-
fied by type of immunosuppressive drugs. Awareness of
the risk for HBV reactivation is particularly important in
the era of ART simplification with regimens not contain-
ing NRTIs active against HBV.
There were no new direct-acting antivirals (DAAs)
licensed for the treatment of HCV since the last Guideline
revision. The HCV treatment recommendations table was
split into two parts, with one table listing the preferred
treatment options, and a second table listing the
alternative options (Table 2, 3). The recommendations
for the management of DAA treatment failures were
updated.
Acute HCV infection was renamed “recently acquired
HCV infection” in accordance with the recent European
AIDS Treatment Network consensus conference (NEAT)
statement [6]. Lack of spontaneous clearance and pro-
gression to chronic infection can be predicted reliably by
four weeks after diagnosis in those with less than a
2 9 log10 reduction in HCV RNA [7]. Accordingly, this
situation is considered as early chronic HCV infection
and immediate DAA therapy is recommended. DAA treat-
ment is recommended as in treatment-na€ıve noncirrhotic
individuals (except for those with pre-existing liver cir-
rhosis), as several trials failed to demonstrate noninferior-
ity of shortened treatment courses [6].
Finally, the recommendations on the management of
viral hepatitis D and E in PLWH were expanded.
Table 3 DAA HCV treatment options (except for persons pretreated with protease or NS5A inhibitors) to be used if preferred option is not
avaible
HCV GT Treatment regimen
Treatment duration and RBV usage
Noncirrhotic Compensated cirrhotic Decompensated cirrhotic CTP class B/C
1 and 4 OBV/PTV/r + DSV 8a–12 weeks in GT 1b 12 weeks in GT 1b Not recommended
OBV/PTV/r + DSV + RBV 12 weeks in GT 1a 24 weeks in GT 1a Not recommended
OBV/PTV/r + RBV 12 weeks in GT 4 Not recommended
SOF + DCV  RBV 12 weeks  RBVb 12 weeks with RBVc
SOF/VEL/VOX 8 weeksd 12 weeks Not recommended
2 SOF + DCV 12 weeks 12 weeks with RBV
SOF/VEL/VOX 8 weeksd 12 weeks Not recommended
3 SOF + DCV  RBV 12 weeks  RBVe or 24 weeks without RBV 24 weeks with RBV
SOF/VEL/VOX 8 weeksd 12 weeks Not recommended
5 and 6 SOF + DCV  RBV 12 weeks  RBV or 24 weeks without RBVf 12 weeks with RBVc
SOF/VEL/VOX 8 weeksd 12 weeks Not recommended
CTP, child-Turcotte-Pugh; DAA, direct-acting antiviral; DCV, daclatasvir; DSV, dasabuvir; EBR, elbasvir; GLE, glecaprevir; GT, genotype; GZR, grazoprevir;
LDV, ledipasvir; NS5A, Nonstructural protein 5A; OBV, ombitasvir; PIB, pibrentasvir; PTV/r, paritaprevir/RTV; RAS, resistance-associated substitution;
RBV, ribavirin; SOF, sofosbuvir; VEL, velpatasvir; VOX, voxilaprevir.
a
8 weeks of treatment without RBV only in PLWH without cirrhosis.
b
Addition of RBV in GT1a treatment-experienced PLWH, but not in PLWH without NS5A RASs, if RAS testing is available.
c
In PLWH intolerant to RBV, treatment may be prolonged to 24 weeks. RBV can be omitted in treatment-na€ıve or -experienced PLWH with compen-
sated cirrhosis without baseline NS5A RAS.
d
Extension of treatment to 12 weeks in DAA treatment-experienced PLWH.
e
Addition of RBV only in treatment-experienced persons with baseline NS5A RASs, if RAS testing available; if these PLWH are intolerant to RBV, treat-
ment may be prolonged to 24 weeks without RBV.
f
In treatment-experienced (exposure to IFN/RBV/SOF) PLWH, treat with RBV for 12 weeks or prolong treatment to 24 weeks without RBV.
© 2020 The Authors.
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Opportunistic infection (OI) section
A new table is included at the start of the revised OI sec-
tion, providing guidance on when to start ART in the
presence of OIs and in particular TB, cryptococcal menin-
gitis and cytomegalovirus (CMV) end-organ disease.
Also added is a new table on immune reconstitution
inflammatory syndrome (IRIS), including definitions of
paradoxical and unmasking IRIS, along with recommen-
dations on prevention and management.
For the 2019 update, extensive revisions on how to
manage drug-resistant TB in PLWH were made. The rec-
ommendations are in line with the most recent World
Health Organization (WHO) recommendations to use four,
preferably oral and presumed effective TB drugs for the
first six months of intensive treatment, followed by treat-
ment with three active drugs for 12–14 months depend-
ing on response [8]. In addition, a new table on
recommended TB drug doses and key adverse effects has
been added.
Also new is the addition of talaromycosis, which is rel-
evant in PLWH who have lived in Asia. The table con-
tains recommendations on diagnosis, treatment and
secondary prophylaxis.
Minor edits have been made to the other individual OIs,
most importantly for Pneumocystis jiroveci pneumonia
(PCP) and Toxoplasma gondii infection, where primary
prophylaxis can now be stopped already at CD4 counts
> 100 cells/lL and if viral load has been undetectable for
> 3 months. For nontuberculous mycobacteria, primary
prophylaxis in the case of a CD4 count < 50 cells/lL is no
longer recommended if ART is started.
Conclusions
The 2019 version of the EACS Guidelines has undergone
substantial updates in all sections and has been expanded
with new sections on DDIs and other prescribing issues in
PLWH. The Guidelines are available in four different for-
mats and translated into Chinese, French, German, Japa-
nese, Portuguese, Russian and Spanish.
Appendix 1:
Guidelines Panel Members 2019
Medical secretariat: the EACS Medical Secretariat is
responsible for the coordination and update of the EACS
guidelines based on the recommendations from the five
EACS panels.
Guidelines Chair: Manuel Battegay (Basel, Switzerland);
Guidelines Coordinator: Lene Ryom (Copenhagen, Den-
mark).
Panel members:
HIV treatment:
Chair: Jose Arribas (Madrid, Spain); Vice-Chair: Jean-
Michel Molina (Paris, France); Young Scientist: Rosa De
Miguel Buckley (Madrid, Spain); Antonella d’Arminio
Monforte (Milan, Italy), Manuel Battegay (Basel, Switzer-
land), Margherita Bracchi (London, UK), Nikos Dedes
(Athens, Greece), Andrzej Horban (Warsaw, Poland),
Christine Katlama (Paris, France), Inga Latysheva (Saint
Petersburg, Russia), Jens D. Lundgren (Copenhagen, Den-
mark), Sheena McCormack (London, UK), Cristina Mussini
(Modena, Italy), Anton Pozniak (London, UK), Federico
Pulido (Madrid, Spain), Francois Raffi (Nantes, France),
Peter Reiss (Amsterdam, The Netherlands), Hans-J€urgen
Stellbrink (Hamburg, Germany), Marta Vasylyev (Lviv,
Ukraine).
Drug–drug interactions:
Chair: Catia Marzolini (Basel, Switzerland); Vice-Chair:
Giovanni Guaraldi (Modena, Italy); Sara Gibbons (Liver-
pool, UK), Francoise Livio (Lausanne, Switzerland).
Comorbidities:
Chair: Patrick Mallon (Dublin, Ireland); Vice-Chair:
Alan Winston (London, UK); Young Scientist: Aoife Cotter
(Dublin, Ireland); Manuel Battegay (Basel, Switzerland),
Georg Behrens (Hannover, Germany), Mark Bower (Lon-
don, UK), Paola Cinque (Milan, Italy), Simon Collins (Lon-
don, UK), Juliet Compston (Cambridge, UK), Stephane De
Wit (Brussels, Belgium), Leonardo M. Fabbri (Modena,
Italy), Christoph A. Fux (Aarau, Switzerland), Magnus
Gisslen (Gothenburg, Sweden), Giovanni Guaraldi (Mod-
ena, Italy), Justyna D. Kowalska (Warsaw, Poland), Jens
D. Lundgren (Copenhagen, Denmark), Esteban Martınez
(Barcelona, Spain), Catia Marzolini (Basel, Switzerland),
Jose M. Miro (Barcelona, Spain), Eugenia Negredo (Barce-
lona, Spain), Neil Poulter (London, UK), Peter Reiss (Ams-
terdam, The Netherlands), Lene Ryom (Copenhagen,
Denmark), Giada Sebastiani (Montreal, Canada).
Viral hepatitis co-infections:
Chair: Andri Rauch (Bern, Switzerland); Vice-Chair:
Sanjay Bhagani (London, UK); Young Scientist: Charles
Beguelin (Bern, Switzerland); Juan Berenguer (Madrid,
Spain), Christoph Boesecke (Bonn, Germany), Raffaele
Bruno (Pavia, Italy), Svilen Konov (London, UK), Karine
Lacombe (Paris, France), Stefan Mauss (D€usseldorf, Ger-
many), Luıs Mend~ao (Lisbon, Portugal), Lars Peters
(Copenhagen, Denmark), Massimo Puoti (Milan, Italy),
J€urgen K. Rockstroh (Bonn, Germany).
Opportunistic infections:
Chair: Ole Kirk (Copenhagen, Denmark); Vice-Chair:
Paola Cinque (Milan, Italy); Young Scientist: Daria
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Podlekareva (Copenhagen, Denmark); Juan Ambrosioni
(Barcelona, Spain), Nathalie De Castro (Paris, France),
Gerd F€atkenheuer (Cologne, Germany), Hansjakob Furrer
(Bern, Switzerland), Jose M. Miro (Barcelona, Spain), Cris-
tiana Oprea (Bucharest, Romania), Anton Pozniak (Lon-
don, UK), Alain Volny-Anne (Paris, France). WAVE
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Governing board members:
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Spain), Fiona Mulcahy (Immediate, Past President) (Dublin,
Ireland), Antonella d’Arminio Monforte (Milan, Italy), Man-
uel Battegay (Basel, Switzerland), Georg Behrens (Hannover,
Germany), Christine Katlama (Paris, France), Jens D. Lund-
gren (Copenhagen, Denmark), Cristina Mussini (Modena,
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(London, UK), Peter Reiss (Amsterdam, The Netherlands),
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References
1 European AIDS Clinical Society Guidelines v10.0. November
2019.
2 Ryom L, Boesecke C, Gisler V et al. Essentials from the 2015
European AIDS Clinical Society (EACS) guidelines for the treatment
of adult HIV-positive persons.HIVMed 2016; 17: 83–88.
3 Zash R, Holmes L, Diseko M et al. Neural tube defects and
antiretro-viral treatment regimens in Botswana. N Engl J Med
2019; 381: 827–840.
4 Wandeler G, Mauron E, Atkinson A et al. Incidence of
hepatocellular carcinoma in HIV/HBV-coinfected patients on
tenofovir therapy: relevance for screening strategies. J Hepatol
2019; 71: 274–280.
5 Swanepoel CR, Atta MG, D’Agati VD et al. Kidney disease in
the setting of HIV infection: conclusions from a kidney
disease: improving global outcomes (KDIGO) controversies
conference. Kidney Int 2018; 93: 545–559.
6 European AIDS Treatment Network (NEAT) consensus
conference statement. June 2019. Available at www.neat-id.
org (accessed 12 December 2019).
7 Boesecke C, Martinez EM, Nelson M et al. Fueling the
epidemic: low rates of spontaneous clearance of acute HCV
coinfection. CROI. Boston, MA, March 2018 [Abstract 129].
8 WHO consolidated guidelines on drug-resistant tuberculosis
treatment. Geneva: World Health Organization 2019. Available
at https://apps.who.int/iris/bitstream/handle/10665/311389/
9789241550529-eng.pdf (accessed 12 December 2019).
© 2020 The Authors.
HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association
HIV Medicine (2020)
8 L Ryom et al.
